DA
VRTX icon

Drake & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Drake & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-708
Closed -$329K – 106
2024
Q3 		$329K Buy
708
+241
+52% +$116K 0.11% 70
2024
Q2 		$219K Sell
467
-57
-11% -$24.7K 0.08% 74
2024
Q1 		$219K Buy
+524
New +$222K 0.08% 74

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Drake & Associates's VRTX Position: Q4 2024 in Review

Drake & Associates sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 708 shares — an estimated $329K sold.

Drake & Associates first reported a position in VRTX in Q1 2024 and held it in 3 quarters. The position peaked at $329K in Q3 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Drake & Associates reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Drake & Associates sold 708 Vertex Pharmaceuticals shares in Q4 2024, an estimated $329K.
  • Drake & Associates first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Drake & Associates's Vertex Pharmaceuticals position peaked at $329K in Q3 2024.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Drake & Associates's 13F filing for Q4 2024, filed 10 Feb 2025.